Injecting lab-grown human heart muscle cells into failing hearts during bypass surgery produced no tumors at 12 months and no sustained ventricular tachycardia, according to a 20-patient randomized trial published August 19, 2026 in Nature Medicine. Both were the trial’s prespecified safety targets. But every patient who received the cells developed an abnormal heart rhythm within the first month, and the authors write that future studies will have to work out whether the benefit is worth that risk.
Key takeaways
- The trial hit both of its primary safety targets: no tumor formation at 12 months and no sustained ventricular tachycardia in months 1 through 6.
- All 10 patients who got cells developed accelerated idioventricular rhythm, usually 5 to 7 days after the injection. Two had ventricular tachycardia faster than 140 beats per minute, which resolved completely after cardioversion.
- The paper reports no significant difference between the groups in ejection fraction, heart chamber size, scar size, NYHA class, or quality-of-life scores at 12 months.
What the study found
The HEAL-CHF trial enrolled 20 patients, 18 male and 2 female, with advanced heart failure and a left ventricular ejection fraction of 45% or below. Everyone got coronary artery bypass grafting. Half were randomly assigned to also receive intramyocardial injections of allogeneic heart muscle cells grown from induced pluripotent stem cells. The other half were not injected. This was a single-center trial, and the sponsor, HELP Therapeutics, calls the product HiCM-188.
The primary endpoint was safety, defined as sustained ventricular tachycardia between months 1 and 6 and tumor formation at 12 months. Neither occurred in either group.
The rhythm events are worth reading closely. All 10 cell-therapy patients developed accelerated idioventricular rhythm, typically emerging 5 to 7 days after transplantation, according to the study. Clinically significant ventricular tachycardia above 140 beats per minute occurred in 2 patients, peaked at 2 to 3 weeks after the procedure, and resolved completely after cardioversion.
On efficacy, the cell group did significantly better on three secondary measures: 6-minute walk distance, blood flow through the heart muscle on nuclear imaging, and relative wall thickening. There were no significant between-group differences in ejection fraction, ventricular volumes, scar size, NYHA functional class, or Minnesota Living with Heart Failure Questionnaire scores at 12 months.
Dr. Kumar’s take
Two failure modes have shadowed pluripotent-cell heart therapy for twenty years. One is teratoma, a tumor formed by leftover undifferentiated stem cells. The other is lethal arrhythmia from a patch of new muscle beating on its own schedule. A randomized design that returns zero tumors at 12 months is the real news here, bigger than any walk-distance number.
The arrhythmia box is only half checked. Sustained ventricular tachycardia did not happen, and that was the prespecified bar. But 10 out of 10 patients developing engraftment arrhythmia is not a footnote, and two needing cardioversion is not either. The authors say as much: in view of the arrhythmic events, future work will need to determine the risk-to-benefit ratio.
The efficacy signal deserves a light grip. Twenty patients, open-label, and the control group was uninjected rather than sham-injected. Both arms also got a bypass, which improves symptoms on its own. With that design, you cannot cleanly separate what the cells did from what the surgery did.
It is worth being clear on symptom class specifically. The paper lists NYHA functional class among the outcomes with no significant difference between the groups at 12 months, so any headline saying the cells moved patients into a better symptom class is not coming from the journal report. It is also a different setup from the lab-grown heart muscle patches that helped failing hearts pump stronger, so the two results should not be stacked together.
Twelve months is a short window for a tumor endpoint involving pluripotent cells.
What it means for you
Nothing you can act on today. HiCM-188 is investigational and not approved anywhere. The company says a Phase III trial is enrolling in China and a Phase I is starting in the United States at the Texas Heart Institute.
If a clinic is offering you a stem cell injection for heart failure right now, it is not this. This was done during open-heart surgery inside a registered trial, with monitoring for engraftment arrhythmia built in.
For anyone living with ischemic heart failure, the levers that work are still the ordinary ones: guideline-directed medication taken consistently, revascularization when the anatomy calls for it, and rhythm monitoring. This trial is a real step toward a future therapy, not a present one.